The SEC has resolved insider trading allegations with a Massachusetts resident concerning Sage Therapeutics, Inc, after his alleged liquidation of shares in the company on the basis of “extremely restricted” FDA-related information.
According to the SEC’s complaint, Brian Suthoff allegedly avoided losses of nearly $20,000 by trading in advance of
Register for free to keep reading
To continue reading this article and unlock full access to GRIP, register now. You’ll enjoy free access to all content until our subscription service launches in early 2026.
- Unlimited access to industry insights
- Stay on top of key rules and regulatory changes with our Rules Navigator
- Ad-free experience with no distractions
- Regular podcasts from trusted external experts
- Fresh compliance and regulatory content every day